Focus: FT Global Pharma & Biotech Conference 2012Value at risk? |
What lies ahead for global life sciences companies in the new health care era as they transform to stay ahead of the game?
Deloitte was proud to join over 300 senior life science executives and industry leaders from around the world at the Financial Times Global Pharmaceutical & Biotechnology Conference (follow #FTPharma on Twitter) to debate, discuss, and respond to today's critical industry issues.
Deloitte launched the third edition of its Measuring the return from pharmaceutical innovation report and leaders were active session participants.
- Couldn't attend in person? The Financial Times has made videos of all sessions available online for free download.
Contact us and explore these Deloitte reports to learn more about the FT Global Pharma/Biotech Conference topics, life sciences industry services, and insights provided by Deloitte member firms around the world.
Featured content
 |
Measuring the return from pharmaceutical innovation 2012: Is R&D earning its investment? Download this Deloitte UK and Thomson Reuters report, the third in an annual series exploring the pharmaceutical industry’s performance in generating a return from its investment in new product innovation. |
 |
Value at risk? The role for life sciences in the new health care era Listen to the podcast, featuring Deloitte life science and health care industry leaders discussing FT Global Pharmaceutical & Biotechnology Conference 2012 topics, including value based pricing (VBP), innovation, and evolving operating models. |
Related content
 |
Value-based pharmaceutical pricing: Deloitte Insights video To transition from volume-based models to value-based pricing, companies must start with the basics. Watch this episode of Deloitte Insights to learn more. |
 |
2012 U.S. survey of health care consumers Fifth annual survey of over 4,000 U.S. adult consumers about their interest in and ability to operate in a consumer health care market and interaction with health care providers, payers, and life sciences companies. |
 |
The case for change The health care landscape is expected to evolve over the next decade, find out about how changes will affect multiple stakeholders, including providers, health plans, employers, state governments, and biopharma companies. |
 |
Physician Payment Sunshine Act Physicians and life sciences companies coming to terms with transparency? New Deloitte survey, in collaboration with Forbes Insights, explores physician and life sciences executive opinions on transparency in the health care industry. |
 |
Global health care reform and life sciences In recent years, important markets worldwide have enacted, or intend to enact, major health care reforms. Participate in a new EIU/Deloitte survey that is exploring reform impact on the life sciences industry. |
